209 related articles for article (PubMed ID: 8626110)
1. Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients.
Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Romanini C
Gynecol Oncol; 1996 Apr; 61(1):16-21. PubMed ID: 8626110
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell activity in stage I endometrial carcinoma: correlation with nuclear grading, myometrial invasion, and immunoreactivity of proliferating cell nuclear antigen.
Garzetti GG; Ciavattini A; Goteri G; Tranquilli AL; Muzzioli M; Fabris N; De Nictolis M; Romanini C
Gynecol Oncol; 1994 Oct; 55(1):111-4. PubMed ID: 7525425
[TBL] [Abstract][Full Text] [Related]
3. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract][Full Text] [Related]
4. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
5. The 72-kDa metalloproteinase immunostaining in cervical carcinoma: relationship with lymph nodal involvement.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Gynecol Oncol; 1996 Feb; 60(2):271-6. PubMed ID: 8631550
[TBL] [Abstract][Full Text] [Related]
6. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
7. Recurrence patterns in locally advanced cervical carcinoma: role of nodal status and 72-kDa metalloproteinase index.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; De Nictolis M; Romanini C; Biagini G
Gynecol Oncol; 1996 Apr; 61(1):83-9. PubMed ID: 8626123
[TBL] [Abstract][Full Text] [Related]
8. Decrease in tumor volume and histologic response to intraarterial neoadjuvant chemotherapy in patients with cervical and endometrial adenocarcinoma.
Fujiwaki R; Takahashi K; Kitao M
Gynecol Oncol; 1997 May; 65(2):258-64. PubMed ID: 9159335
[TBL] [Abstract][Full Text] [Related]
9. The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma.
Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; Mychalczak BR; McKee B; Hoskins WJ; Barakat RR
Cancer; 2002 Jul; 95(2):316-21. PubMed ID: 12124832
[TBL] [Abstract][Full Text] [Related]
10. [Significance of proliferating cell nuclear antigen (PCNA) index and microvessel density (MVD) in endometrial carcinoma].
Xiao L; Tang LD
Ai Zheng; 2005 Jan; 24(1):19-22. PubMed ID: 15642194
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma.
Hamel NW; Sebo TJ; Wilson TO; Keeney GL; Roche PC; Suman VJ; Hu TC; Podratz KC
Gynecol Oncol; 1996 Aug; 62(2):192-8. PubMed ID: 8751548
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
[TBL] [Abstract][Full Text] [Related]
13. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients.
Wang X; Huang Z; Di W; Lin Q
Arch Gynecol Obstet; 2005 Jul; 272(2):136-41. PubMed ID: 15666177
[TBL] [Abstract][Full Text] [Related]
14. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
15. Pathologic stage I-II endometrial carcinoma in the elderly: radiotherapy indications and outcome.
Citron JR; Sutton H; Yamada SD; Mehta N; Mundt AJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1432-8. PubMed ID: 15275729
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
[TBL] [Abstract][Full Text] [Related]
17. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma.
Schwab KV; O'Malley DM; Fowler JM; Copeland LJ; Cohn DE
Gynecol Oncol; 2009 Jan; 112(1):146-9. PubMed ID: 18937970
[TBL] [Abstract][Full Text] [Related]
20. Proliferating cell nuclear antigen as a prognostic factor after total mesorectal excision of stage II-III rectal cancer.
Huh JW; Kim HR; Kim YJ
Ann Surg Oncol; 2009 Jun; 16(6):1494-500. PubMed ID: 19267156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
